日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

一项针对EGFR突变、PD-L1阳性、未接受过酪氨酸激酶抑制剂治疗的晚期非小细胞肺癌患者的帕博利珠单抗II期研究

Lisberg, A; Cummings, A; Goldman, J W; Bornazyan, K; Reese, N; Wang, T; Coluzzi, P; Ledezma, B; Mendenhall, M; Hunt, J; Wolf, B; Jones, B; Madrigal, J; Horton, J; Spiegel, M; Carroll, J; Gukasyan, J; Williams, T; Sauer, L; Wells, C; Hardy, A; Linares, P; Lim, C; Ma, L; Adame, C; Garon, Edward B

Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center

单中心 KEYNOTE-001 研究中,治疗相关不良事件可预测非小细胞肺癌患者的临床结局改善

Lisberg, Aaron; Tucker, D Andrew; Goldman, Jonathan W; Wolf, Brian; Carroll, James; Hardy, Ariana; Morris, Karolyn; Linares, Paulina; Adame, Carlos; Spiegel, Marshall L; Wells, Courtney; McKenzie, Jordan; Ledezma, Blanca; Mendenhall, Melody; Abarca, Phillip; Bornazyan, Krikor; Hunt, Jaime; Moghadam, Nima; Chong, Natalie; Nameth, Danielle; Marx, Caitlin; Madrigal, John; Vangala, Sitaram; Shaverdian, Narek; Elashoff, David; Garon, Edward B

Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation

患者报告结果与临床及临床试验文件的一致性较低

Fares, Charlene M; Williamson, Timothy J; Theisen, Matthew K; Cummings, Amy; Bornazyan, Krikor; Carroll, James; Spiegel, Marshall L; Stanton, Annette L; Garon, Edward B